TRIM33 and dermatomyositis: We also seek to investigate correlation between cfDNA and laboratory parameters and compare cfDNA profiles between anti-TIF1g antibody-positive dermatomyositis patients with and without malignancies, as well as other MSA phenotypes, to assess its potential in distinguishing phenotypes.